Appili Therapeutics Inc Total Assets
Appili Therapeutics Inc total assets. Based on the latest financial reports, Appili Therapeutics Inc (APLI) holds total assets worth CA$547.91K CAD (≈ $396.35K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Appili Therapeutics Inc (APLI) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Appili Therapeutics Inc (2017–2025)
Total assets of Appili Therapeutics Inc from 2017 to 2025. This chart illustrates how Appili Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Appili Therapeutics Inc (APLI) share price today for real-time trading data and today's change.
Appili Therapeutics Inc - Asset Composition Analysis
Appili Therapeutics Inc Total Assets Breakdown (March 2025)
Appili Therapeutics Inc total assets breakdown as of March 2025. Appili Therapeutics Inc's total assets of CA$547.91K consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 40.5% |
| Accounts Receivable | CA$1.67 Million | 55.1% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$19.04K | 0.6% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Appili Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore APLI working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Appili Therapeutics Inc's current assets represent 99.4% of total assets in 2025, an increase from 97.9% in 2017.
- Cash Position: Cash and equivalents constituted 40.5% of total assets in 2025, down from 52.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 55.1% of total assets.
Appili Therapeutics Inc Competitors by Total Assets
Key competitors of Appili Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
Appili Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.03 | 0.14 | 3.96 |
| Quick Ratio | 0.03 | 0.14 | 3.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-15.66 Million | CA$-12.84 Million | CA$13.65 Million |
Appili Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Appili Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 103.5% |
| Total Assets | CA$3.03 Million |
| Market Capitalization | $464.29K USD |
Valuation Analysis
Below Book Valuation: The market values Appili Therapeutics Inc's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Appili Therapeutics Inc's assets grew by 103.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Appili Therapeutics Inc (2017–2025)
The table below shows the annual total assets of Appili Therapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | CA$3.03 Million ≈ $2.19 Million |
+103.48% |
| 2024-03-31 | CA$1.49 Million ≈ $1.08 Million |
-52.42% |
| 2023-03-31 | CA$3.13 Million ≈ $2.27 Million |
-62.18% |
| 2022-03-31 | CA$8.28 Million ≈ $5.99 Million |
-54.79% |
| 2021-03-31 | CA$18.32 Million ≈ $13.25 Million |
+63.93% |
| 2020-03-31 | CA$11.17 Million ≈ $8.08 Million |
+63.48% |
| 2019-03-31 | CA$6.84 Million ≈ $4.94 Million |
-4.95% |
| 2018-03-31 | CA$7.19 Million ≈ $5.20 Million |
+180.06% |
| 2017-03-31 | CA$2.57 Million ≈ $1.86 Million |
-- |
About Appili Therapeutics Inc
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paro… Read more